Trial Profile
A phase I study of salmeterol/fluticasone-propionate administered via Spiromax for treatment of asthma and chronic obstructive pulmonary disease
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2014
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 04 Dec 2014 New trial record